Familial polyposis coli: the management of desmoid tumor bleeding

There is currently no standard treatment for desmoid tumors (DTs) associated with familial polyposis coli (FAP). Familial adenomatous polyposis in DT patients is sometimes a life-threatening condition. We enrolled all consecutive patients with FAP treated at Unit of General Surgery and Transplant, U...

Full description

Saved in:
Bibliographic Details
Published inOpen medicine (Warsaw, Poland) Vol. 14; no. 1; pp. 572 - 576
Main Authors Calogero, Armando, Sagnelli, Caterina, Carlomagno, Nicola, Tammaro, Vincenzo, Candida, Maria, Vernillo, Antonio, Peluso, Gaia, Minieri, Gianluca, Sica, Antonello, Ciccozzi, Massimo, Santangelo, Michele, Dodaro, Concetta Anna
Format Journal Article
LanguageEnglish
Published Poland De Gruyter 01.01.2019
Walter de Gruyter GmbH
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:There is currently no standard treatment for desmoid tumors (DTs) associated with familial polyposis coli (FAP). Familial adenomatous polyposis in DT patients is sometimes a life-threatening condition. We enrolled all consecutive patients with FAP treated at Unit of General Surgery and Transplant, University of Naples Federico II and evaluated the incidence of DTs on FAP between 1996 and 2016. We observed 45 consecutive patients with FAP; of these 5 were DT-FAP-associated. All 5 cases with FAP were young women, age 25 to 65 years, previously treated by colectomy. Of these, 4 patients presented a parietal localization and had been treated with a wide surgical exeresis; one patient had an intra-abdominal, mesenteric tumor that was unresectable at laparotomy. We performed CT-guided drainage, ureteral stenting, medical therapy (sulindac+tamoxifene), and chemotherapy (dacarba-zine+doxorubicine).All patients were alive and underwent follow-ups for 5 years post-surgery; only 1 patient with parietal localization showed a local relapse after 2 years. We propose a modulated approach to the single patient with FAP, with surgery as treatment of choice for parietal localization disease and integrating different kinds of therapies (surgery alone or associated with RT, CT) for the intra-abdominal tumor.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Equally contributed to this work, designed the study, and wrote the manuscript.
Antonello Sica, Oncology and Hematology, AOU “Luigi Vanvitelli”, Naples, Italy
Massimo Ciccozzi, Medical Statistics and molecular Epidemiology Unit, Campus Bio-Medico University, Rome, Italy
ISSN:2391-5463
2391-5463
DOI:10.1515/med-2019-0064